These three companies have the resources and the positioning to survive the harshest of economic conditions.
Based on year-to-date performance, these popular stocks are on track for their 12th consecutive year of gains.
Shares of potential COVID-19 developers have surged with each bit of news. But one offers better prospects for investors.
Big gains are probably in the cards for these recently unstoppable stocks.
This analyst thinks Novavax’s stock has little upside left.
The company's second quarter lined up almost perfectly with the 10-week shutdown of the retail industry.
But several regional banks are in the COVID-19 loan program
Two of America's biggest cruisers are figuring out how to resume cruising safely.
Investors continue to wait for detailed phase 1 data for the coronavirus vaccine.
A job posting implies that a subscription plan is in the works.